Identification of novel viral receptors with cell line expressing viral receptor-binding protein

Mei Mei1,2*, Jianqiang Ye1,2*, Aijian Qin1,2,3, Lin Wang1,2, Xuming Hu1,2, Kun Qian1,2,3 & Hongxia Shao1,2,3

1Ministry of Education Key Lab for Avian Preventive Medicine, Yangzhou University, No.12 East Wenhui Road, Yangzhou, Jiangsu, 225009, P. R. China, 2Key Laboratory of Jiangsu Preventive Veterinary Medicine, Yangzhou University, Yangzhou, 225009, P. R. China, 3Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, P. R. China.

The viral cell receptors and infection can be blocked by the expression of the viral receptor-binding protein. Thus, the viral cell receptor is an attractive target for anti-viral strategies, and the identification of viral cell receptor is critical for better understanding and controlling viral disease. As a model system for viral entry and anti-retroviral approaches, avian sarcoma/leukosis virus (ASLV, including the A–J ten subgroups) has been studied intensively and many milestone discoveries have been achieved based on work with ASLV. Here, we used a DF1 cell line expressed viral receptor-binding protein to efficiently identify chicken Annexin A2 (chANXA2) as a novel receptor for retrovirus ALV-J (avian leukosis virus subgroup J). Our data demonstrate that antibodies or siRNA to chANXA2 significantly inhibited ALV-J infection and replication, and over-expression of chANXA2 permitted the entry of ALV-J into its non-permissible cells. Our findings have not only identified chANXA2 as a novel biomarker for anti-ALV-J, but also demonstrated that cell lines with the expression of viral receptor-binding protein could be as efficient tools for isolating functional receptors to identify novel anti-viral targets.

The binding of the viral surface protein to the receptors expressed in host cells triggers the viral infection and pathogenesis1–3. Thus, viral cell receptors not only determine the viral tropism, but also provide host targets for antiviral strategies. For example, the multiple identified cell receptors and co-receptors for HIV (e.g., CD4, CCR5, and CXCR4) are clarifying the molecular details of HIV entry and creating efficient approaches for AIDS interventions4–7. And the sialic acid analogues that mimic the influenza virus receptors have been shown clinical effects against influenza infection8. The receptor for SARS coronavirus (SARS-CoV), angiotensin-converting enzyme 2, has also been reported as a potential therapeutic target for SARS-CoV9,10.

As a model system for viral entry, avian sarcoma/leukosis virus (ASLV, including A–J ten subgroups) has been studied intensively, and several important receptors for ASLV entry have been identified by traditional methods11–15. Because saturation of the viral cell receptors of susceptible cells via the expression of viral receptor-binding protein can block the corresponding viral infection16–18, such virus-resistant cells might be efficient tools for the isolation of the functional receptors for viral entry and novel anti-viral biomarkers. To test this possibility, we used an ALV-J-resistant cell line (pcDNA-env_DF1) that expresses ALV-J Env in the ALV-J-susceptible cell line DF1 as a tool for isolating novel receptors for ALV-J. Through this approach, we identified chicken Annexin A2 (chANXA2) as a novel ALV-J receptor.

Results

Identification of chANXA2 as a novel binding protein to ALV-J Env. The pcDNA-env_DF1 cell line expressing ALV-J Env protein was previously constructed and shown to be resistant to ALV-J infection19. To use this cell line to isolate novel functional receptors for ALV-J, we first extracted the membrane proteins from the pcDNA-env_DF1 cells and then performed immunoprecipitation with the single monoclonal antibody (mAb) JE-9, which is specific to ALV-J Env19. Silver staining for SDS-PAGE of the immunoprecipitation revealed several different bands in the lysate that was immunoprecipitated with ALV-J-specific mAb JE-9 and not with the control antibody (Fig. 1A). Mass spectrometry further revealed that one of these bands was chicken Annexin A2 (chANXA2), a member of the annexin family20.
To further confirm this finding, a recombinant adenovirus rAd-SUJ-rlgGFc expressing fusion protein SUJ-rlgGFc (Fig. 1B) was constructed and the purified SUJ-rlgGFc was used to precipitate the membrane protein extracted from DF1 cells. SDS-PAGE and Mass spectrometry (MS) revealed that chANXA2 was also found in the precipitate with purified SUJ-rlgGFc, but not in the precipitate with rabbit IgG control protein (Fig. 1C). Moreover, we cloned the full-length cDNA encoding chANXA2 from the total RNA of the DF1 cells into the pcDNA3.1 vector, and did co-transfection with plasmid pcDNA3.1-EnvJ and chANXA2 in 293T cells. The co-immunoprecipitation (co-IP) using mAb JE9 revealed that ALV-J Env protein could efficiently interact with chANXA2 (Fig. 1D). All these data clearly demonstrate that chANXA2 is identified as a novel binding protein to ALV-J Env.

**Antibody or siRNA to chANXA2 significantly inhibiting ALV-J infection and replication.** To test whether chANXA2 serves as a functional receptor for ALV-J infection, we used antibodies against chANXA2 to perform blocking assays to evaluate the effects of chANXA2 on ALV-J infection in DF1 cells. Our results revealed that the viral infection/replication of ALV-J was significantly inhibited in groups that had been treated with anti-chANXA2. As shown in Fig. 2A, there was little visible immunofluorescence in the cells that were treated with 50 or 25 μg/ml of the antibody against chANXA2 in the IFA. Moreover, only a few positive cells were found among the cells that were treated with 5 μg/ml of antibody against ANXA2. In contrast, many positive cells were found among the cells that were treated with the control IgG and among the untreated cells. Consistent with the IFA results, the viral titres of the cells that were treated with 50 and 25 μg/ml of antibody against chANXA2 were approximately 50-fold and 10-fold less, respectively, than those of the cells that were treated with the control IgG (Fig. 2B). The inhibitory effect on ALV-J infection/replication conferred by the antibody against ANXA2 was also confirmed by western blot (Fig. 2C). As a viral control, we also performed a blocking assay for ALV-A infection in the DF1 cells. As described in Fig. 2D, the p27 expression levels of ALV-A in the groups that were treated with the antibody against chANXA2 were similar to those of the mock group, which indicates that the antibody against ANXA2 could not inhibit ALV-A infection/replication in DF1 cells. These data clearly demonstrate that blocking chANXA2 with a specific antibody can effectively and specially inhibit the infection/replication of ALV-J.

To further evaluate whether the low expression of chANXA2 could confer resistance to ALV-J infection in its susceptible cells, we did siRNA against chANXA2 in DF1 cell, and then tested the effect on the ALV-J infection/replication. As described in Fig. 3A, real-time PCR showed that all four siRNA against chANXA2 tested could efficiently reduce chANXA2 mRNA level. And the western blot showed that all these four siRNA against chANXA2 tested could significantly decrease the infection/replication of ALV-J in DF1 cells (Fig. 3B).

**Over-expression of chANXA2 permitting the entry of ALV-J into its non-permissible cells.** To extend our finding and investigate whether the over-expression of the chANXA2 protein in ALV-J non-permissible cells could induce susceptibility to ALV-J infection, the replication of ALV-J in the 293T cells transfected with chANXA2 was analysed by IFA and real-time PCR. Real-time PCR revealed that the relative expression of the ALV-J envelope gene was increased in the chANXA2-transfected 293T cells at 72 h post-infection (Fig. 3B). However, the 293T cells that were transfected with chANXA2 exhibited no visible specific fluorescence with the JE9 antibody to ALV-J Env. These data indicate that ALV-J could enter the 293T cells that were over-expressing chANXA2, but the viral replication of the ALV-J was restricted in the transfected 293T cells. To further confirm this finding, we also transfected chANXA2 into goose embryo fibroblast (GEF) cells in which the ALV-J could not grow. After 48 h, the transfected GEFs were infected with ALV-J. The GEF cells were maintained in DMEM medium for 2 days. Next, the mixture of GEF cells and supernatants were inoculated into fresh DF1 cells. Interestingly, as shown in Fig. 4B, virus was recovered from the GEF cells transfected with chANXA2, but no virus was obtained from the GEF cells that were transfected with the control plasmid. Together, these data demonstrate that the over-expression of chANXA2 in 293T or GEF cells can support ALV-J entry into these ALV-J non-permissible cells.

**Discussion**

Viral infection and pathogenesis are initiated by the binding of the viral surface protein to its cellular receptor. And the identification of viral cell receptor is critical not only for better understanding the molecular events for viral infection, but also for developing novel anti-viral strategies. The traditional methods for identifying viral
receptors mainly depend on the expression and purification of the viral binding proteins. In this study, we reported the first isolation and identification of chANXA2 as a novel functional receptor for ALV-J entry by using an ALV-J-resistant cell line without the procedure of viral protein purification. And the isolation of chANXA2 as ALV-J Env binding protein was further confirmed in this study by using fusion protein SUJ-rIgGFc, which had used in the traditional method for ALV receptor isolation. And the interaction between ALV-J Env and chANXA2 was confirmed using Co-IP. Our findings highlight that virus-resistant cell lines that are constructed through the expression of viral receptor-binding protein in susceptible cells can be widely used as an efficient tool for the isolation of functional receptors for viral entry and novel anti-viral targets.

The blocking of chANXA2 with a specific antibody and siRNA against chANXA2 can both effectively inhibit the infection/replication of ALV-J suggests chANXA2 can be as a novel host marker for anti-ALV-J strategies and as a new model system for examining the molecular events of retroviral entry into the host. To our knowledge, this is the first demonstration of the inhibition of ALV-J infection by antibodies against one of the host’s protein, which highlights the fact that chANXA2 can serve as a novel functional receptor for ALV-J entry and provide a host marker for anti-ALV-J strategies. In 2006, chNHE1 was identified by Ning et al as a receptor for ALV-J infection, and Kucerova et al also recently demonstrated that a single amino-acid substitution of W38 in chNHE1 abrogates ALV-J infection. However, no data have yet shown that antibodies to chNHE1 can block or inhibit ALV-J infection so far. In present study, we did not rule out the fact that chNHE1 is a receptor for ALV-J infection, but we did identify chANXA2 as a novel receptor for ALV-J infection. However, the potential interaction between chNHE1 and chANXA2 need to be investigated. Either chNHE1 requires chANXA2 or chANXA2 requires chNHE1 when they as ALV-J receptors need to be further tested. The over-expression of chANXA2 could permit the entry of ALV-J into ALV-J non-permissible cells further supports the conclusion of chANXA2 as a novel functional receptor for ALV-J infection.

ANXA2 is a member of the annexin family and plays vital roles in regulating cellular functions including the endo- and exocytotic pathways, the generation of plasmin and calcium-dependent F-actin filament bundling. It has been reported that ANXA2 can link HCMV to a phospholipid membrane and enhance virus-membrane fusion and is a receptor for respiratory syncytial virus. More recently, ANXA2 was also reported to play critical roles in the viral entry/replication of human papillomavirus type 16, enterovirus 71 and hepatitis C virus. Furthermore, ANXA2 plays a cell type-dependent role in regulating HIV infectivity. These previous reports regarding ANXA2 indicate that, because ALV-J Env binding protein was isolated using an ALV-J resistant cell line in the present study, ANXA2 might also play vital roles in ALV-J infection. The roles of ANXA2 as viral receptor or in viral infectivity reported may relate with its endo- and exocytotic pathways. However, the mechanism of these novel functions of ANXA2 need to be further eluci-

Figure 2 | (Qin) Inhibition of ALV-J infection by antibodies to ANXA2. The DF1 cells that had been pre-treated with antibodies against ANXA2 were infected with ALV-J or ALV-A, and the replications of ALV-J and ALV-A in the treated cells were analysed. (A), IFA analysis using JE9; (B), TCID50 analysis for viral titres; (C), western blot analysis for the expression of Env from ALV-J in the DF1 cells that were treated with antibodies. Lane 1, mock; lane 2, goat IgG (50 μg/ml); lane 3, anti-ANXA2 (5 μg/ml); lane 4, anti-ANXA2 (25 μg/ml); lane 5, anti-ANXA2 (50 μg/ml); (D), western blot analysis for the expression of p27 of ALV-A in the DF1 cells treated with antibodies. Lane 1, mock; lane 2, goat IgG (50 μg/ml); lane 3, anti-ANXA2 (50 μg/ml).
Geese embryo fibroblast (GEF), DF-1 and pcDNA-env_DF1 cells were maintained in medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. Cells and viruses

Methods

Myeloma and haemangioamas induced by ALV-J infection. Further studies will also shed light on the roles of chANXA2 in myelomas and haemangioamas induced by ALV-J infection.

Figure 3 | (Qin) siRNA against chANXA2 in DF1 cells. DF1 cells were transfected with control siRNA; lane 6, DF1 cells with Mock. siRNA Mix (co-transfected with 535, 105 and 299), 535, 105 and 299 against chANXA2 respectively; lane 5, DF1 cells transfected with siRNA; lane 6, DF1 cells with Mock.

Preparation of membrane extracts. pcDNA-env_DF1 cells and DF1 cells in 100 mm dishes were harvested by scraping with a rubber policeman and homogenised with NP-40 lysis buffer containing 25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol (pH 7.4) and a protease inhibitor cocktail (Roche). Intact cells and nuclei in the resulting extract were sedimented by centrifugation at 4°C for 5 min at 6000 g. The membrane proteins in the supernatant were sedimented by an additional spin at 13200 g for 1 h at 4°C and resuspended in 1% NP-40 lysis buffer. All extracts were stored at −80°C until use.

Immunoprecipitation and mass spectrometry. The membrane proteins from the pcDNA-env_DF1 cells were immunoprecipitated with the monoclonal antibody JE9, which is specific to ALV-J Env and Resin A (Thermo Scientific). The membrane proteins from the DF1 cells were precipitated with the purified protein SUJ-rIgGFc and protein A agarose (Beyotime, China). Precipitated proteins were separated by SDS-PAGE, stained with a Silver Stain Kit (Thermo Scientific) and analysed with mass spectrometry. In Co-immunoprecipitation (Co-IP), 293T cells were co-transfected with plasmid pcDNA3.1-EnvJ, and chANXA2 for 48 h, and then lysed in lysis buffer. The cell lysates were immunoprecipitated with mAb JE9 at 4°C overnight, and then incubated with protein A agarose for 1 hr. After three washes in lysis buffer, the lysates were analyzed and then analyzed using JE9 and antibody against chANXA2 in western blot.

Antibody blocking assay. The DF1 cells were pre-treated with different concentrations of anti-ANXA2 (C-16, Santa Cruz) for 2 h and then the cells were infected with ALV-J or ALV-A at an MOI of 5. The cells were maintained in DMEM with 1% fetal bovine serum and different concentrations of antibodies. Normal goat-IgG was used as the isotype control antibody in the blocking assay. The replication of ALV-J in the treated cells was analysed by IFA, real-time PCR, TCID50 and western blot.

Figure 4 | (Qin) Infection of the chANXA2-transfected cells. Geese embryo fibroblasts (GEF) and 293T cells were transfected with chANXA2, and the transfected cells were then infected with ALV-J at an MOI of 5. (A). The replication of ALV-J in the 293T cells transfected with ANXA2 was measured by real-time PCR; (B). The replication of ALV-J in the GEF cells transfected with ANXA2 was measured IFA after inoculating the homogenate from the transfected GEF cells to the DF1 cells.
Table 1 | Sequences of primers for Real-time PCR and siRNA against chANXA2

| Name          | Sequence (5’ to 3’)                           | RT-PCR Arc                             | siRNA Arc                             |
|---------------|----------------------------------------------|----------------------------------------|----------------------------------------|
| ALV-J gp37    | Forward: TGCGTGCTGGTTATAATTTC                | RT-PCR: ALV-J gp37                      | Forward: CCUCCACUGGCUAUAUGCGACAGUGA   |
|               | Reverse: AATTGCTAAGGTTCTGGAAGTGA             |                                        | Reverse: CCUGGUGUCUUCGCGAAGCAAUAU     |
| chANXA2       | Forward: ATCACATCTCTGCAAAACCG                |                                        | Reverse: CUACUAGGGACUAUUGCGACAGUGA    |
| Chicken 18S   | Reverse: TAAGTGCTGCAAGAAAGTTC                |                                        | Forward: UGCGACCUUUAUGUCGUCUGUCA      |
| Human β-actin | Forward: TCAGAAACCTACCTCAACCTC              |                                        | Reverse: CAUGCAAGACAGUUAAGUGCGCAGA    |
|               | Reverse: CATACCTCGTCTGCGTAGT                |                                        |                                        |
| 105           |                                              |                                        |                                        |
| 299           |                                              |                                        |                                        |
| 535           |                                              |                                        |                                        |

infected with ALV-J at an MOI of 5 (5 TCID₅₀/cell based on the titer obtained from DF1 cells) for 2 h followed by three washes with PBS and treatment with acid glycine (pH 3.0) for 1 min. After further three washes with PBS, the 293T and GEF cells were maintained in DMEM with 1% FBS for 48 h. For the 293T cells, the replication of ALV-J was analysed with IFA and real-time PCR at 12 h, 24 h, 48 h and 72 h post-infection. For the GEF cells, the cells and supernatants were homogenised and inoculated into the DF1 cells, and viral replication in the DF1 cells was analysed with IFA with JEF at day 7 post-inoculation.

**Real-time PCR.** RNA was isolated from the cell lysates using the Total RNA Miniprep Kit (Axygen) according to the manufacturer’s instructions. The RNA was reverse-transcribed using PrimerScript RT Reagent Kit (Takara) with primers that are specific to the ALV-J gp37 and ANXA2 gene according to the manufacturer’s instruction. Chicken 18S and human β-actin were used as an internal control in this assay. The primers of real-time PCR for ALV-J gp37, ANXA2 and chicken 18S and human β-actin were listed in Table 1.

**Indirect immunofluorescence assay (IFA) and western blot analysis.** Indirect immunofluorescence assays (IFAs) were performed on the 293T and DF1 cells. The monoclonal antibody JEF, which is specific to the Env of ALV-J, was used as the primary antibody. FITC-goat anti-mouse IgG was used as the secondary antibody. Western blot analyses were performed on cell lysates. JEF or anti-β-actin or anti-chANXA2 antibody was used as the primary antibody, and HRP-conjugated goat anti-mouse or HRP-conjugated donkey anti-goat was used as the secondary antibody (Santa Cruz).

1. Mothes, W., Boerger, A. L., Narayan, S., Cunningham, J. M. & Young, J. A. Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. *Cell* 103, 679–689 (2000).
2. Lindemann, D., Steffen, I. & Pohlmann, S. Cellular entry of retroviruses. *Adv. Exp. Med. Biol.* 790, 128–149 (2013).
3. Dimitrov, D. S. Virus entry: molecular mechanisms and biomedical applications. *Nat. Rev. Microbiol.* 2, 109–122 (2004).
4. Tran, K. et al. Vaccine-elicited primates antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. *Proc. Natl Acad. Sci. USA* 111, E738–E747 (2014).
5. Rogers, W. M. et al. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HBV infection. *Aids* 18, 25–36 (2004).
6. Martin, K. A. et al. CD4-independent binding of SIV gp120 to rhesus CCR5. *Science* 278, 1470–1473 (1997).
7. Hutter, G. et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N. Engl. J. Med.* 360, 692–698 (2009).
8. Oldfors, S. & Bergstrom, T. Glycoconjugate ganglios as viral receptors. *Ann. Med.* 37, 154–172 (2005).
9. Adata, O. et al. Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus Entry That Act by Three Distinct Mechanisms. *J. Virol.* 87, 8017–8028 (2013).
10. Dimitrov, D. S. The secret life of ACE2 as a receptor for the SARS virus. *Cell* 115, 652–653 (2003).
11. Bates, P., Young, J. A. & Varmaus, H. E. A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor. *Cell* 74, 1043–1051 (1993).
12. Brojatsch, J., Naughton, J., Rolls, M. M., Zingler, K. & Young, J. A. CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukemia-sarcoma viruses and mediates apoptosis. *Cell* 87, 845–855 (1996).
13. Adkins, H. B. et al. Identification of a cellular receptor for subgroup E avian leukemia virus. *Proc. Natl Acad. Sci. USA* 94, 11617–11622 (1997).
14. Chai, N. & Bates, P. Na⁺/H⁺ exchanger type 1 is a receptor for pathogenic subgroup J avian leukemia virus. *Proc. Natl Acad. Sci. USA* 103, 5531–5536 (2006).
15. Elleder, D. et al. The receptor for the subgroup C avian sarcoma and leukaosis viruses, Thy, is related to mammalian butyrophilins, members of the immunoglobulin superfamily. *J. Virol.* 79, 10408–10419 (2005).
16. Crittenenden, L. B. & Salter, D. W. A transgene, alv, that expresses the envelope of subgroup A avian leukemia virus reduces the rate of congenital transmission of a field strain of avian leukemia virus. *Poultry. Sci.* 71, 799–806 (1992).
17. Hunt, H. D., Lee, L. F., Foster, D., Silva, R. F. & Fadly, A. M. A genetically engineered cell line resistant to subgroup J avian leukemia virus infection (C/J). *Virology* 264, 205–210 (1999).
18. Ye, J. Q. A., Shao, H., Liu, H., Jin, W. & Liu, Y. Development of chicken embryo fibroblast cell line resistant to subgroup J avian leukaosis virus (ALV-J) infection. *Zing. Du. Xue. Bao.* 21, 456–460 (2005).
19. Qin, A., Lee, L. F., Fadly, A., Hunt, H. & Cui, Z. Development and characterization of monoclonal antibodies to subgroup J avian leukaosis virus. *Avian. Dis.* 45, 938–945 (2001).
20. Okuse, K. et al. Annexin II light chain regulates sensory neuron-specific sodium channel expression. *Nature* 417, 653–656 (2002).
21. Kucerova, D. et al. Nonconserved tryptophan of the 31 cell surface receptor for subgroup J avian leukaosis virus discriminates sensitive from resistant avian species. *J. Virol.* 87, 8399–8407 (2013).
22. Donato, R. & Russo-Marie, F. The annexins: structure and functions. *Cell calcium* 26, 83–89 (1999).
23. Gerke, V. & Mose, S. E. Annexins: from structure to function. *Physiol. Rev.* 82, 331–371 (2002).
24. Kim, J. & Hajjar, K. A. Annexin II: a plasminogen-plasminogen activator co-receptor. *Front. Biosci.* 7, d341–348 (2002).
25. Raynor, C. M., Wright, J. F., Waisman, D. M. & Pryzbyla, I. E. Annexin II enhances cytoamegalovirus binding and fusion to phospholipid membranes. *Biochemistry* 38, 5089–5095 (1999).
26. Malhotra, R. et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. *Microbes. Infect.* 5, 123–133 (2003).
27. Dziduszko, A. & Ozbun, M. A. Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes. *J. Virol.* 87, 7502–7515 (2013).
28. Yang, S. L., Chou, Y. T., Wu, C. N. & Ho, M. S. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. *J. Virol.* 85, 11809–11820 (2011).
29. Rai, T., Mosoao, A. & Resh, D. M. Annexin 2 is not required for human immunodeficiency virus type 1 particle production but plays a cell type-dependent role in regulating infectivity. *J. Virol.* 84, 9783–9792 (2010).
30. Bachus, P. et al. Role of annexin A2 in the production of infectious hepatitis C virus particles. *J. Virol.* 84, 5775–5789 (2010).
31. Payne, L. N. & Nair, V. The long view: 40 years of avian leukaosis research. *Avian. Pathol.* 41, 11–19 (2012).
32. Reed, L. J. & Muench, H. A simple method for estimating 50 percent endpoints. *Am. J. Hyg.* 74, 493 (1938).
M.M., A.J.Q., J.Q.Y. and K.Q. contributed to the writing of the manuscript. M.M., L.W. and J.Q.Y. prepared figures. All authors reviewed the manuscript.

Additional information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Mei, M. et al. Identification of novel viral receptors with cell line expressing viral receptor-binding protein. Sci. Rep. 5, 7935; DOI:10.1038/srep07935 (2015).